Hi, thanks for the opportunity and congrats on the deal. So, first of all, you talked about the management team, so are these guys staying on? And do you have a certain run-out and other factors attached for a certain period of time?
And you have had really good growth until quite recently, and especially automotive manufacturing now that’s started picking up. So, can you talk about the type of clients, and sort of the work that Nagarro does in this segment.
Hi, thanks for the opportunity. Sandeep, you spoke about how there were some delays in decision making…
One second, I will try again. Hear me now?
Hi, thanks and congrats on a good quarter. So, wanted to ask you about the healthcare vertical in particular, there are concerns that providers and payers are under a lot of pressure because there are unexpected costs in Medicare customers and also lower payments from the US federal government. I know that you have literally small wallet share in these custome rs, but do you see this as an opportunity, or do you think there are possible headwin ds in these accounts?
Thanks, Sandeep. And on banks specifically, you know, BFSI we have seen very good results by the banks but people are worried that there too spending might actually have an impact on discretionary programs. I think there is an overall a perception that Persistent is perhaps more exposed to discretionary programs you know and when it comes to cost takeout you may not benefit, could you talk a bit about that.
Thank you. Sandeep, congratulations at the end of a good quarter. What I want to ask you about the top client. You said that this is a plan ned ramp down and that this is the last deal that you had signed in FY23. Is there any re-negotiation as well in this or this was just productivity improvement and other things that were baked in right from the time you signed the contract? Contract will say yes b ut the client actually changed any part of the contract or restructured it?
Thank you. Lastly on margins, can we think about margin improvement being possible when the demand environment improves? You were saying that you have over invested a bit, deliberately in sales. So can we see that normalize when demand comes back?
Congratulations on a really good quarter. One question is on the Healthcare side. If I look at your breakup of customers, it looks like there is now pharmaceutical companies, payers, providers, and clinical research organizations, is this a change from the whole s cientific instruments and medical devices focus that you've had maybe three years back, are most of these new customers?
I also see that you are beyond the top -10 customers, the traction continues. So, can you explain also that you're seeing some wins from your Private Equity channel. Anything else that you could call out, some of these customers their potential to take them to the top-10?
Hi, thank you. Thanks for the detailed presentation. I think it would have been better appreciated over a full day analysts’ meet rather than a 90-minute call, but let's do it. Thanks for laying this out. Just wanted to check on the margin aspiration beyond FY27. So, we have TCS at the top end at 26% today, Infosys in the 20-21% range, and HCL below that around 18-19%. So are you saying that you'd actually get to 18-19% at least, or cross that going into 20%? And is that the aspiration?
Thanks for that.
Hi-tech, media entertainment is a vertical that is challenged for most, but you have done well. Is this due to new deal wins, or is it just a matter of different set of exposures, such as lower telecom?